Loading...

Brilliant Violet 605™ anti-mouse CD279 (PD-1) Antibody

Pricing & Availability
Clone
29F.1A12 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, Programmed Death-1, PDCD1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
29F.1A12_BV605_013112
Con-A and IL-2 stimulated C57BL/6 splenocytes (3 days) were stained with CD3 PE and CD279 (clone 29F.1A12) Brilliant Violet 605™.
  • 29F.1A12_BV605_013112
    Con-A and IL-2 stimulated C57BL/6 splenocytes (3 days) were stained with CD3 PE and CD279 (clone 29F.1A12) Brilliant Violet 605™.
Compare all formats See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
135219 125 µL $237
Check Availability


Need larger quantities of this item?
Request Bulk Quote
135220 50 µg $292
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.

Application References

(PubMed link indicates BioLegend citation)
  1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
  2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
  3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
  4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
  5. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  2. Wrzner K, et al. 2021. EBioMedicine. 63:103197. PubMed
  3. Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed
  4. Lee JH, et al. 2022. Cell Rep. 38:110485. PubMed
  5. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  6. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  7. Eschweiler S 2023. Cell Reports. 42(2):112040. PubMed
  8. Stravokefalou V, et al. 2023. Front Immunol. 13:1014802. PubMed
  9. Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed
  10. van Elsas MJ, et al. 2023. J Immunother Cancer. 11:. PubMed
  11. Verma S, et al. 2016. J Virol. 90: 650 - 658. PubMed
  12. Wang D, et al. 2018. Immunity. 48:659. PubMed
  13. Stathopoulou C, et al. 2020. Immunity. 49(2):247-263.e7.. PubMed
  14. Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed
  15. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  16. Baram T, et al. 2021. Cells. 10:. PubMed
  17. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  18. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  19. Lindenstrøm T et al. 2017. EBioMedicine. 27:27-39 . PubMed
  20. DeLong JH, et al. 2019. Immunohorizons. 3:13. PubMed
  21. Porsche CE, et al. 2021. JCI Insight. 6:. PubMed
  22. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  23. Rodriguez AB, et al. 2021. Cell Reports. 36(3):109422. PubMed
  24. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  25. Marro BS, et al. 2019. Cell Rep. 29:3293. PubMed
  26. Levi J, et al. 2020. J Nucl Med. . PubMed
  27. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  28. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  29. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
  30. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  31. Vogel AB, et al. 2021. Nature. 592:283. PubMed
  32. Xu S, et al. 2021. Immunity. . PubMed
  33. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  34. Kurniawan H, et al. 2020. Cell Metabolism. 31(5):920-936. PubMed
  35. Tan X, et al. 2021. Sci Adv. 7: . PubMed
  36. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  37. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  38. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  39. Sandu I, et al. 2020. Cell Reports. 32(8):108078. PubMed
  40. Fu Y, et al. 2021. Front Cell Dev Biol. 9:689727. PubMed
  41. Engel I, et al. 2016. Nat Immunol. 10.1038/ni.3437. PubMed
  42. Wen J, et al. 2020. Cell Rep. 31:107566. PubMed
  43. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  44. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  45. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  46. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
RRID
AB_2562616 (BioLegend Cat. No. 135219)
AB_2562616 (BioLegend Cat. No. 135220)

Antigen Details

Structure
A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution

Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.

Function
Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor
B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, T cells
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Other Formats

View All CD279 Reagents Request Custom Conjugation
Description Clone Applications
PE anti-mouse CD279 (PD-1) 29F.1A12 FC
Purified anti-mouse CD279 (PD-1) 29F.1A12 FC,IHC-F,Block,ELISA
PerCP/Cyanine5.5 anti-mouse CD279 (PD-1) 29F.1A12 FC
APC anti-mouse CD279 (PD-1) 29F.1A12 FC
Biotin anti-mouse CD279 (PD-1) 29F.1A12 FC
FITC anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Cyanine7 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 421™ anti-mouse CD279 (PD-1) 29F.1A12 FC,SB
Brilliant Violet 605™ anti-mouse CD279 (PD-1) 29F.1A12 FC
APC/Cyanine7 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 785™ anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Dazzle™ 594 anti-mouse CD279 (PD-1) 29F.1A12 FC
Alexa Fluor® 647 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 711™ anti-mouse CD279 (PD-1) 29F.1A12 FC
GoInVivo™ Purified anti-mouse CD279 (PD-1) 29F.1A12 FC
APC/Fire™ 750 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 510™ anti-mouse CD279 (PD-1) 29F.1A12 FC
Ultra-LEAF™ Purified anti-mouse CD279 (PD-1) 29F.1A12 FC,IHC-F,Block
APC/Fire™ 810 anti-mouse CD279 (PD-1) Antibody 29F.1A12 FC
PE/Fire™ 810 anti-mouse CD279 (PD-1) Antibody 29F.1A12 FC
PE/Cyanine5 anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Fire™ 640 anti-mouse CD279 (PD-1) 29F.1A12 FC
Spark Red™ 718 anti-mouse CD279 (PD-1) 29F.1A12 FC
PerCP/Fire™ 806 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 750™ anti-mouse CD279 (PD-1) 29F.1A12 FC
PerCP/Fire™ 780 anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Fire™ 700 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 650™ anti-mouse CD279 (PD-1) 29F.1A12 FC
Spark Blue™ 574 anti-mouse CD279 (PD-1) (Flexi-Fluor™) 29F.1A12 FC
Spark PLUS B550™ anti-mouse CD279 (PD-1) 29F.1A12 FC
Go To Top Version: 4    Revision Date: 09/11/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account